Functional analysis of oxidative stress-induced hepatocarcinogenic genes for molecular target treatment
Project/Area Number |
23590995
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Gastroenterology
|
Research Institution | Jikei University School of Medicine |
Principal Investigator |
|
Co-Investigator(Renkei-kenkyūsha) |
MOGUSHI Kaoru 順天堂大学, 医学(系)研究科, 助教 (60569292)
|
Project Period (FY) |
2011-04-28 – 2015-03-31
|
Project Status |
Completed (Fiscal Year 2014)
|
Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2013: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2011: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
Keywords | 肝発癌 / 酸化ストレス / 肝腫瘍原性遺伝子 / 網羅的遺伝子発現解析 / mRNA / microRNA / siRNA / 網羅的解析 |
Outline of Final Research Achievements |
Persistent liver injury caused by various etiology is involved in hepatocarcinogenesis, which develops through different pathways. Since the most common pathogenesis is persistent exposure to oxidative stress, oxidative stress-induced gene could be one of the most basic hepatocarcinogenic genes. IQGAP1 knockdown resulted in reduced activities of migration and invasion in some hepatoma cell lines, but not in others. Cells with high IQGAP1 expression levels were poorly-differentiated carcinomas with high migration/invasion activities. These cell properties were closely related to IQGAP1. Vimentin also played a critical role in the properties of some cell lines, indicating that knockdown of genes specific to each cancer cell is required to reduce the migration and invasion activities. Furthermore, IQGAP1 with a tumor promotion activity could have an inhibitory activity against tumor growth, suggesting that IQGAP1 has conflicting properties in a cell- and/or microRNA-dependent manner.
|
Report
(5 results)
Research Products
(64 results)
-
[Journal Article] Safety and Efficacy of Partial Splenic Embolization in Telaprevir-based Triple Therapy for Chronic Hepatitis C2015
Author(s)
Kondo C, Atsukawa M, Tsubota A, Shimada N, Abe H, Itokawa N, Nakagawa A, Fukuda T, Matsushita Y, Nakatsuka K, Kawamoto C, Iwakiri K, Aizawa Y, Sakamoto C.
-
Journal Title
Internal Medicine
Volume: 54
Issue: 2
Pages: 119-126
DOI
NAID
ISSN
0918-2918, 1349-7235
Related Report
Peer Reviewed
-
[Journal Article] Factors associated with sustained virological response in 24-week telaprevir-based triple therapy for chronic hepatitis C genotype 1b patients with the IL28B minor genotype2015
Author(s)
Abe H, Tsubota A, Shimada N, Atsukawa M, Kato K, Takaguchi K, Asano T, Chuganji Y, Sakamoto C, Toyoda H, Kumada T, Ide T, Sata M, Aizawa Y.
-
Journal Title
Hepatol Res
Volume: 45
Issue: 4
Pages: 387-36
DOI
Related Report
Peer Reviewed
-
[Journal Article] Relationship between HCV dynamics and sustained virological responses in chronic hepatitis C genotype 1b patients treated with telaprevir-based triple therapy2014
Author(s)
Nakagawa A, Atsukawa M, Tsubota A, Shimada N, Abe H, Kondo C, Itokawa N, Arai T, Hashimoto S, Matsushita Y, Fukuda T, Nakatsuka K, Iwakiri K, Kawamoto C, Aizawa Y, Sakamoto C.
-
Journal Title
Eur J Gastroenterol Hepatol
Volume: 26
Issue: 12
Pages: 1329-1334
DOI
Related Report
Peer Reviewed
-
[Journal Article] Predictors of response to 24-week telaprevir-based triple therapy for treatment-naïve genotype 1b chronic hepatitis C patients2014
Author(s)
Abe H, Tsubota A, Shimada N, Atsukawa M, Kato K, Takaguchi K, Asano T, Chuganji Y, Sakamoto C, Toyoda H, Kumada T, Ide T, Sata M, Aizawa Y.
-
Journal Title
Gastroenterol Res Pract
Volume: 2014
Pages: 549709-549709
DOI
Related Report
Peer Reviewed
-
[Journal Article] Pretreatment prediction of the outcome of response-guided peginterferon-α and ribavirin therapy for chronic hepatitis C2014
Author(s)
Masaki N, Sugiyama M, Shimada N, Tanaka Y, Nakamuta M, Izumi N, Watanabe S, Tsubota A, Komatsu M, Masaki T, Enomoto N, Yoneda M, Murata K, Ito K, Koike K, Mizokami M.
-
Journal Title
J Gastroenterol Hepatol
Volume: 29
Issue: 12
Pages: 1996-2005
DOI
Related Report
Peer Reviewed
-
[Journal Article] Serum 25(OH)D3 levels affect treatment outcomes for telaprevir/peg-interferon/ribavirin combination therapy in genotype 1b chronic hepatitis C2014
Author(s)
Atsukawa M, Tsubota A, Shimada N, Abe H, Kondo C, Itokawa N, Nakagawa A, Iwakiri K, Kawamoto C, Aizawa Y, Sakamoto C.
-
Journal Title
Dig Liver Dis
Volume: 46
Issue: 8
Pages: 738-743
DOI
Related Report
Peer Reviewed
-
-
-
[Journal Article] Effect of fluvastatin on 24-week telaprevir-based combination therapy for hepatitis C virus genotype 1b-infected chronic hepatitis C2014
Author(s)
Atsukawa M, Tsubota A, Shimada N, Kondo C, Itokawa N, Nakagawa A, Fukuda T, Matsushita Y, Narahara Y, Osada Y, Yamaguchi H, Nakatsuka K, Iwakiri K, Kawamoto C, Sakamoto C.
-
Journal Title
Eur J Gastroenterol Hepatol
Volume: 26
Issue: 7
Pages: 781-787
DOI
Related Report
Peer Reviewed
-
[Journal Article] A 48-week telaprevir-based triple combination therapy improves sustained virological response rate in previous non-responders to peginterferon and ribavirin with genotype 1b chronic hepatitis C: A multicenter study.2014
Author(s)
Shimada N, Tsubota A, Atsukawa M, Abe H, Ide T, Takaguchi K, Chuganji Y, Toyoda H, Yoshizawa K, Ika M, Sato Y, Kato K, Kumada T, Sakamoto C, Aizawa Y, Sata M.
-
Journal Title
Hepatol Res
Volume: 2014 Mar (Epub ahead of print)
Issue: 14
DOI
Related Report
Peer Reviewed
-
[Journal Article] Serum 25-hydroxy- vitamin D3 levels affect treatment outcome in pegylated-interferon/ ribavirin combination therapy for compensated cirrhotic patients with HCV genotype 1b and high viral load.2014
Author(s)
Atsukawa M, Tsubota A, Shimada N, Kondo C, Itokawa N, Nakagawa A, Hashimoto S, Fukuda T, Matsushita Y, Narahara Y, Iwakiri K, Nakatsuka K, Kawamoto C, Sakamoto C.
-
Journal Title
Hepatol Res
Volume: 2014 Jan (Epub ahead of print)
Issue: 13
Pages: 1277-1285
DOI
Related Report
Peer Reviewed
-
-
[Journal Article] α-Fetoprotein is a surrogate marker for predicting treatment failure in telaprevir-based triple combination therapy for genotype 1b chronic hepatitis C Japanese patients with the IL28B minor genotype.2014
Author(s)
Shimada N, Tsubota A, Atsukawa M, Abe H, Ika M, Kato K, Sato Y, Kondo C, Sakamoto C, Tanaka Y, Aizawa Y.
-
Journal Title
J Med Virol
Volume: 86
Issue: 3
Pages: 461-472
DOI
Related Report
Peer Reviewed
-
-
[Journal Article] Risk factors for long-term persistence of serum hepatitis B surface antigen following acute hepatitis B virus infection in Japanese adults2014
Author(s)
Ito K, Yotsuyanagi H, Yatsuhashi H, Karino Y, Takikawa Y, Saito T, Arase Y, Imazeki F, Kurosaki M, Umemura T, Ichida T, Toyoda H, Yoneda M, Mita E, Yamamoto K, Michitaka K, Maeshiro T, Tanuma J, Tanaka Y, Sugiyama M, Murata K, Masaki N, Mizokami M; Japanese AHB Study Group
-
Journal Title
Hepatology
Volume: 59
Issue: 1
Pages: 89-97
DOI
Related Report
Peer Reviewed
-
[Journal Article] Hepatic stellate cells that coexpress LRAT and CRBP-1 partially contribute to portal fibrogenesis in patients with human viral hepatitis.2014
Author(s)
Nagatsuma K, Hano H, Murakami K, Shindo D, Matsumoto Y, Mitobe J, Tanaka K, Saito M, Maehashi H, Owada M, Ikegami M, Tsubota A, Ohkusa T, Aizawa Y, Takagi I, Tajiri H, Matsuura T.
-
Journal Title
Liver Int
Volume: 34
Issue: 2
Pages: 243-252
DOI
Related Report
Peer Reviewed
-
[Journal Article] Efficacy of alfacalcidol on PEG-IFN/ribavirin combination therapy for elderly patients with chronic hepatitis C: a pilot study.2013
Author(s)
Atsukawa M, Tsubota A, Shimada N, Kondo C, Itokawa N, Nakagawa A, Hashimoto S, Fukuda T, Matsushita Y, Kidokoro H, Narahara Y, Nakatsuka K, Iwakiri K, Kawamoto C, Sakamoto C.
-
Journal Title
Related Report
Peer Reviewed
-
-
-
-
-
[Journal Article] New proposal for response-guided peg-interferon-plus- ribavirin combination therapy for chronic hepatitis C virus genotype 2 infection.2013
Author(s)
Abe H, Aida Y, Ishiguro H, Yoshizawa K, Seki N, Miyazaki T, Itagaki M, Sutoh S, Ika M, Kato K, Shimada N, Tsubota A, Aizawa Y.
-
Journal Title
J Med Virol
Volume: 85
Issue: 9
Pages: 1523-1533
DOI
Related Report
Peer Reviewed
-
[Journal Article] Platelet count and sustained virological response in hepatitis C treatment.2013
Author(s)
Kanda T, Kato K, Tsubota A, Takada N, Nishino T, Mikami S, Miyamura T, Maruoka D, Wu S, Nakamoto S, Arai M, Fujiwara K, Imazeki F, Yokosuka O.
-
Journal Title
World J Hepatol
Volume: 5
Issue: 4
Pages: 182-188
DOI
Related Report
Peer Reviewed
-
[Journal Article] Peginterferon Alfa-2a plus ribavirin in Japanese patients infected with hepatitis C virus genotype 2 who failed previous interferon therapy.2013
Author(s)
Kanda T, Nakamoto S, Nishino T, Takada N, Tsubota A, Kato K, Miyamura T, Maruoka D, Wu S, Tanaka T, Arai M, Mikami S, Fujiwara K, Imazeki F, Yokosuka O.
-
Journal Title
Int J Med Sci
Volume: 10
Issue: 1
Pages: 43-49
DOI
Related Report
Peer Reviewed
-
[Journal Article] Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.2013
Author(s)
Itokawa N, Atsukawa M, Tsubota A, Kondo C, Hashimoto S, Fukuda T, Matsushita Y, Kidokoro H, Kobayashi T, Narahara Y, Nakatsuka K, Kanazawa H, Iwakiri K, Sakamoto C.
-
Journal Title
J Gastroenterol Hepatol
Volume: 28
Issue: 3
Pages: 443-449
DOI
Related Report
Peer Reviewed
-
[Journal Article] Combination of fluvastatin with pegylated interferon/ribavirin therapy reduces viral relapse in chronic hepatitis C infected with HCV genotype 1b.2013
Author(s)
Atsukawa M, Tsubota A, Kondo C, Itokawa N, Narahara Y, Nakatsuka K, Hashimoto S, Fukuda T, Matsushita Y, Kidokoro H, Kobayashi T, Kanazawa H, Sakamoto C.
-
Journal Title
J Gastroenterol Hepatol
Volume: 28
Issue: 1
Pages: 51-56
DOI
Related Report
Peer Reviewed
-
[Journal Article] Several factors including ITPA polymorphism influence ribavirin-induced anemia in chronic hepatitis C.2012
Author(s)
Tsubota A, Shimada N, Abe H, Yoshizawa K, Agata R, Yumoto Y, Ika M, Namiki Y, Nagatsuma K, Matsudaira H, Fujise K, Tada N, Aizawa Y.
-
Journal Title
World J Gastroenterol
Volume: 18
Issue: 41
Pages: 5879-5888
DOI
Related Report
Peer Reviewed
-
[Journal Article] Contribution of ribavirin transporter gene polymorphism to treatment response in peginterferon plus ribavirin therapy for HCV genotype 1b patients.2012
Author(s)
Tsubota A, Shimada N, Yoshizawa K, Furihata T, Agata R, Yumoto Y, Abe H, Ika M, Namiki Y, Chiba K, Fujise K, Tada N, Aizawa Y.
-
Journal Title
Liver Int
Volume: 32
Issue: 5
Pages: 826-836
DOI
Related Report
Peer Reviewed
-
-
[Journal Article] An open-label randomized controlled study of pegylated interferon/ribavirin combination therapy for chronic hepatitis C with versus without fluvastatin.2012
Author(s)
Kondo C, Atsukawa M, Tsubota A, Itokawa N, Fukuda T, Matsushita Y, Kidokoro H, Kobayashi T, Narahara Y, Nakatsuka K, Kanazawa H, Sakamoto C.
-
Journal Title
J Viral Hepat
Volume: 19
Issue: 9
Pages: 615-622
DOI
Related Report
Peer Reviewed
-
-
-
[Journal Article] Occurrence of hepatocellular carcinoma was not a rare event during and immediately after antiviral treatment in Japanese HCV-positive patients.2011
Author(s)
Kanda T, Imazeki F, Mikami S, Kato K, Shimada N, Yonemitsu Y, Miyauchi T, Arai M, Fujiwara K, Tsubota A, Takada N, Nishino T, Takashi M, Sugiura N, Kimura M, Fukai K, Yokosuka O.
-
Journal Title
Oncology
Volume: 80
Pages: 366-72
Related Report
Peer Reviewed
-
-
[Journal Article] Quantification of hepatitis C virus in patients treated with peginterferon-alfa 2a plus ribavirin treatment by COBAS TaqMan HCV test.2011
Author(s)
Kanda T, Imazeki F, Yonemitsu Y, Mikami S, Takada N, Nishino T, Takashi M, Tsubota A, Kato K, Tanaka T, Nakamoto S, Kurihara T, Arai M, Fujiwara K, Kanai F, Yokosuka O.
-
Journal Title
J Viral Hepat
Volume: 18
Issue: 7
Pages: 292-7
DOI
Related Report
Peer Reviewed
-
[Presentation] Response-guided Peginterferonα+Ribavirin療法施行Genotype2型C型慢性肝炎の治療効果におけるIL28B遺伝子多型測定の意義2014
Author(s)
安部 宏,石黒晴哉,島田紀朋,関 伸嘉,杉田知典,会田雄太,富田陽一,永野智久,板垣宗徳,須藤 訓,坪田昭人,相澤良夫.
Organizer
第40回日本肝臓学会東部会
Place of Presentation
京王プラザ(東京都新宿区)
Year and Date
2014-11-27
Related Report
-
[Presentation] 我が国におけるC型慢性肝炎患者の血清25(OH)D3濃度の特徴2014
Author(s)
中川 愛,厚川正則,島田紀朋,阿部 宏,吉澤 海,浅野 徹,大久保雄介,荒木眞裕,池上 正,糸川典夫,近藤千紗,中塚雄久,忠願寺義通,坪田昭人,相澤良夫,坂本長逸.
Organizer
第40回日本肝臓学会東部会
Place of Presentation
京王プラザ(東京都新宿区)
Year and Date
2014-11-27
Related Report
-
[Presentation] C型慢性肝炎における血清25(OH)D3濃度の特徴についての検討2014
Author(s)
新井泰央,厚川正則,島田紀朋,安部 宏,大久保知美,中川 愛,糸川典夫,近藤千紗,坪田昭人,相澤良夫,川本智章,坂本長逸.
Organizer
第18回日本肝臓学会大会
Place of Presentation
神戸国際展示場・ポートピアホテル・神戸国際会議場(兵庫県神戸市)
Year and Date
2014-10-23
Related Report
-
-
-
[Presentation] C型慢性肝炎に対する3剤併用療法のHCV RNA陰性化時期がSVRに与える影響~48週延長投与例も含めた解析2014
Author(s)
中川 愛,厚川正則,島田紀朋,安部 宏,加藤慶三,近藤千紗,糸川典夫,福田 健,松下洋子,中塚雄久,長田祐二,岩切勝彦,川本智章,坪田昭人,相澤良夫,坂本長逸.
Organizer
第50回日本肝臓学会総会
Place of Presentation
ホテルニューオータニ(東京都千代田区)
Year and Date
2014-05-29
Related Report
-
-
[Presentation] Peg-IFN/ribavirin/telaprevir三剤併用療法における再燃に寄与する因子の検討2014
Author(s)
近藤千紗,厚川正則,島田紀朋,安部 宏,中川 愛,糸川典夫,加藤慶三,福田 健,松下洋子,楢原義之,中塚雄久,岩切勝彦,川本智章,坪田昭人,相澤良夫,坂本長逸.
Organizer
第50回日本肝臓学会総会
Place of Presentation
ホテルニューオータニ(東京都千代田区)
Year and Date
2014-05-29
Related Report
-
-
-
-
[Presentation] IL28B minor genotypeのC型慢性肝炎に対する3剤併用療法における再燃に寄与する因子の検討2014
Author(s)
近藤千紗,厚川正則,島田紀朋,安部 宏,中川 愛,糸川典夫,加藤慶三,福田 健,松下洋子,楢原義之,中塚雄久,岩切勝彦,川本智章,坪田昭人,相澤良夫,坂本長逸.
Organizer
第100回日本消化器病学会総会
Place of Presentation
東京国際フォーラム(東京都千代田区)
Year and Date
2014-04-24
Related Report
-
[Presentation] 代償性肝硬変に対するpeg-IFN/ribavirin併用療法に血清25(OH)D3濃度に与える影響2014
Author(s)
中川 愛,厚川正則,島田紀朋,糸川典夫,近藤千紗,安良岡高志,橋本知実,福田 健,松下洋子,城所秀子,楢原義之,中塚雄久,坪田昭人,岩切勝彦,川本智章,坂本長逸.
Organizer
第100回日本消化器病学会総会
Place of Presentation
東京国際フォーラム(東京都千代田区)
Year and Date
2014-04-24
Related Report
-
[Presentation] C型慢性肝炎IL28B minor genotypeに対するAlfacalcidol併用3剤療法についての検討;Pilot Study2014
Author(s)
糸川典夫,厚川正則,坪田昭人,近藤千紗,橋本知美,松下洋子,福田 健,城所秀子,楢原義之,中塚雄久,金沢秀典,坂本長逸.
Organizer
第100回日本消化器病学会総会
Place of Presentation
東京国際フォーラム(東京都千代田区)
Year and Date
2014-04-24
Related Report
-
-
-
-
[Presentation] 脾腫を伴う血小板低値のC型慢性肝炎に対するPSE先行3剤併用療法の検討.2013
Author(s)
厚川正則,島田紀朋,坪田昭人,近藤千紗,糸川典夫,中川 愛,福田 健,楢原義之,安部 宏,相澤良夫,岩切勝彦,坂本長逸.
Organizer
第17回日本肝臓学会大会
Place of Presentation
グランドホテル高輪・新高輪(東京都港区)
Related Report
-
-
[Presentation] C型慢性肝炎に対するTelaprevirを含む3剤併用療法における治療成績2013
Author(s)
中川 愛,厚川正則,島田紀朋,坪田昭人,糸川典夫,近藤千紗,福田 健,松下洋子,楢原義之,中塚雄久,長田祐二,岩切勝彦,坂本長逸.
Organizer
第17回日本肝臓学会大会
Place of Presentation
グランドホテル高輪・新高輪(東京都港区)
Related Report
-
[Presentation] IL28B gene and very early viral kinetics (Week-1) predict sustained virological response to triple therapy in chronic hepatitis C patients with genotype 1b and high viral load.2013
Author(s)
Ide T, Sata M, Takaguchi K, Toyoda H, Kumada T, Shimada N, Kato K, Tsubota A, Izumi N.
Organizer
The Liver Meeting, The 64th Annual Meeting of the AASLD 2013
Place of Presentation
Washington, DC, USA
Related Report
-
[Presentation] IL28BゲノタイプおよびHCV G1bコア70番アミノ酸置換から見たテラプレビル,リバビリン,ペグインターフェロン3剤併用療法の治療効果の検討.2013
Author(s)
安部 宏,島田紀朋,厚川正則,坪田昭人,関 伸嘉,会田雄太,石黒晴哉,井家麻紀子,加藤慶三,相澤良夫.
Organizer
第49回日本肝臓学会総会
Place of Presentation
京王プラザホテル(東京都新宿区)
Related Report
-
-
[Presentation] TVR3剤併用療法のウイルス陰性化時期別の治療成績の検討.2013
Author(s)
島田紀朋,厚川正則,坪田昭人,安部 宏,加藤慶三,井家麻紀子,佐藤祥之,立花浩幸,米澤 健,戸田剛太郎,相澤良夫.
Organizer
第49回日本肝臓学会総会
Place of Presentation
京王プラザホテル(東京都新宿区)
Related Report
-
[Presentation] C型慢性肝炎に対する3剤併用療法の治療効果に寄与する因子~スタチン併用も含め~.2013
Author(s)
中川 愛,厚川正則,島田紀朋,坪田昭人,近藤千紗,糸川典夫,福田 健,松下洋子,楢原義之,長田祐二,中塚雄久,岩切勝彦,坂本長逸.
Organizer
第49回日本肝臓学会総会
Place of Presentation
京王プラザホテル(東京都新宿区)
Related Report
-
[Presentation] 血小板数低値のC型慢性肝炎に対するPSE先行3剤併用療法について.2013
Author(s)
近藤千紗,厚川正則,島田紀朋,坪田昭人,糸川典夫,中川 愛,橋本知実,福田 健,松下洋子,城所秀子,楢原義之,中塚雄久,金沢秀典,岩切勝彦,坂本長逸.
Organizer
第49回日本肝臓学会総会
Place of Presentation
京王プラザホテル(東京都新宿区)
Related Report
-
-
[Presentation] B型慢性肝炎に対するPeginterferon alfa-2a単独およびSequential Therapy施行時のHBs抗原量の推移に関する検討~多施設共同研究~.2013
Author(s)
神田達郎,厚川正則,島田紀朋,篠崎正美,三上繁,星野容子,加藤慶三,中本晋吾,千葉哲博,新井誠人,今関文夫,坪田昭人,横須賀収.
Organizer
第49回日本肝臓学会総会
Place of Presentation
京王プラザホテル(東京都新宿区)
Related Report
-